Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $24.7400 (-3.47%) ($24.6400 - $26.0500) on Wed. Sep. 23, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4% (three month average) | RSI | 40 | Latest Price | $24.7400(-3.47%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -2% in a week (0% probabilities). VIXM(-36%) VXX(-34%) UUP(-18%) DRIV(-5%) TBT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2% (StdDev 4%) | Hourly BBV | -1.8 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $25.14 | 5 Day Moving Average | $25.42(-2.68%) | 10 Day Moving Average | $25.3(-2.21%) | 20 Day Moving Average | $25.14(-1.59%) | To recent high | -9.1% | To recent low | 35.8% | Market Cap | $3.133b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |